immunization, H37Rv M.tuberculosis (M.tb) was challenged. Five weeks after the challenge of M.tb, mice were sacrificed and C.F.U. of M.tb in lung, liver and spleen were accessed as reported previously.[2,9-11] The C.F.U. of lungs in BCG vaccine alone group was decreased in 1 log compared with non-vaccinated mice group. The combination of the DNA vaccine (HSP65 DNA + IL-12) and BCG using prime-boost method enhanced the prophylactic efficacy (more than ten thousand fold) in the mouse model of TB (BCG prime-DNA vaccine boost). This regimen (BCG-prime then DNA vaccine boost) strongly increased the number of IFN-γ producing cells as compared with BCG vaccine alone (Table 1).

CD8+ CTLs have been considered as critical effectors of protective immunity to M. tuberculosis. This vaccine induced CD8+ CTL against TB, whereas a little or no CTL response was observed in either the naive or BCG-vaccinated mice (Figs. 2 and 3). We used HSP65 DNA-transfected syngenic tumor cells as target cells for CTL. This vaccine augmented the induction of CD8+ CD4- CTL against target cells in vivo. On the other hand, a little or no CTL response was observed in BCG-vaccinated mice (Figs. 2 and 3).

Furthermore, we revealed that CD8+ T cells as well as CD4+ T cells were necessary for the prophylactic effficacy of this vaccine. The administration of anti-CD8 antibody or anti-CD4 antibody during the whole immunization period decreased the antibacterial immunity against TB and increased the number of C.F.U in lungs (Table 2). Simultaneous administration of anti-CD8 and anti-CD4 antibodies resulted in the further increase of the number of C.F.U in lungs (Table 2).

T cell activation by HSP 65+IL-12/HVJ DNA vaccine in the monkey model of TB. We used cynomolgus monkeys and prime-boost methods for the evaluation of our vaccines. We immunized monkeys with BCG Tokyo as a prime vaccine, and then immunize them with this vaccine as a boost vaccine. Survival rate of monkeys vaccinated with BCG prime-HSP65+IL-12 DNA boost was 100%. In contrast, survival rate of monkeys vaccinated with BCG alone was 33%. Thus, prime-boost method showed stronger efficacy than the method vaccinated with BCG alone (data not shown).

IFN-γ production from PBL was the highest level in the monkey group immunized with BCG prime-HSP65+IL-12/HVJ DNA vaccine boost (Fig. 4A). The strongest production of IL-2 from PBL was also observed in same group (Fig. 4B). Thus, in monkey as well as in mouse, we demonstrated that the combination of BCG Tokyo as a prime vaccine and the DNA vaccine as a boost vaccine is suitable method to get the prophylactic efficacies against TB. The prime-boost method efficiently induced the TB-specific CTL and also induced the production of IFN-γ and IL-2.

In Japan, BCG Tokyo vaccine is immunized in all infants. Thus it is expected to function as a prime vaccine. Therefore, we need the administration of novel vaccines (boost vaccines) for adults in Japan. We plan to use similar prime-boost method (BCG prime-DNA vaccine boost) in future clinical trial.

Table 1. ELISPOT assay for IFN-γ antigen-specific responses in the spleens of vaccinated mice following stimulation with HSP65 protein

Vaccination (1st/2nd/3rd)	Number of IFN-γ secreting cells/ (10⁶ splenocytes)		
G1	-/-/-	3	±	1
G2	-/-/BCG	13	±	6
G3	DNA*/DNA/DNA	16	±	4
G4	BCG/DNA/DNA	115	±	12

*DNA means HVJ-Envelope/HSP65 DNA+IL-12 DNA vaccine. Spleen cell cultures were stimulated with rHSP65 protein for 20 h. The number of IFN-γ-secreting cells specific for rHSP65 protein per million cells was determined individually by ELISPOT assay. Results are expressed as the mean ± S.D. of 6 wells of 3 mice per group. The statistically significant differences of the G1 (naïve) group compared with the G2 (BCG alone group), G3 (DNA / DNA / DNA) or G4 (BCG / DNA / DNA) were observed (p < 0.01). The statistically significant difference between G2 group and G4 was observed (p < 0.01). The statistically significant difference between G3 group and G4 was observed (p < 0.01).

Correlation of IL-2 production and the therapeutic efficacy of HSP65+IL-12/HVJ DNA vaccine in the monkey model of TB. This vaccine showed therapeutic efficacy against MDR-TB and XDR-TB as well as drug-sensitive TB in mice.[9,11,12] Therefore, we confirmed the therapeutic efficacy of the DNA vaccine and T cell responses induced by the DNA vaccine in the monkey model of TB. To establish the model of TB, human TB (5 × 10² CFU) was intratracheally instillated in monkeys. After the TB infection, DNA vaccine was injected intramuscularly 9 times, three times a week. Therapeutic effect was evaluated on the basis of survival, ESR, body weight, immune responses, chest X-ray and PPD skin test.

Injection of the therapeutic vaccine improved the survival of monkeys, as compared with the saline (control) group. No death was observed in monkey group treated with HSP65 +IL-12/HVJ DNA vaccine. In contrast, the survival rate of control saline group was 60% (data not shown). The proliferation of PBL after the stimulation with HSP65 was measured to evaluate the immune response. The proliferation of PBL from the monkeys treated with the DNA vaccine was more augmented than that from the monkeys treated with saline (data not shown). IL-2 production from PBL after the stimulation with killed TB H37Ra antigens was also examined. The level of IL-2 was higher in the DNA vaccine-treated group than that in saline control group (Table 3A). In addition, the IL-2 production from PBL after the stimulation with PPD was seemed to correlate with the survival after TB challenge. The level of IL-2 production of died monkeys was significantly lower than that of survived monkeys in saline group at 53days after TB challenge (Table 3B). IL-2 production by the stimulation with HSP65 protein was also extremely low level in died monkeys (data not shown). These data suggested that therapeutic efficacy of this vaccine correlate with the level of IL-2 production.

Induction of CTL by 15K granulysin vaccine. Granulysin is protein especially abundant in CTL and NK cells. It is be classified into two major protein products [15kDa (15K) granulysin and 9kDa (9K) granulysin]. Latter granulysin (9K) exhibits

Figure 2. Induction of CD8+ CTL specific for HSP65 protein and M. tuberculosis by vaccination with HVJ-Envelope/HSP65 DNA+IL-12 DNA. Spleen cells from the naïve, BCG-, and HVJ-Envelope/HSP65 DNA+IL-12 DNA vaccinated mice were obtained eight weeks after the final vaccination. Cytotoxicity was assayed as release of radioactivity from ^{51}Cr-labeled P815 target that had been transfected with HSP65 DNA using conventional ^{51}Cr release assay as described in Materials and Methods.

potent cytotoxic activity against a broad panel of microbial targets, including bacteria, fungi and parasites. Granulysin is present in human CD8+ (and some CD4+) CTLs, NK cells, NKT cells and γ/δ T cells. However, the precise function of 15K granulysin has not yet been elucidated. We found that 15K granulysin was secreted from CD8 positive CTL, could enter into human macrophages and killed M. tuberculosis in the cytoplasm of macrophages. Expression of 15K granulysin protein and mRNA in CD8 positive T cells in the patients with Tuberculosis was significantly lower than those in the healthy volunteers. Moreover, the induction of 15K granulysin production after the stimulation with PPD antigen was suppressed in the supernatants of PBL from TB patients (data not shown).

Recombinant 15K granulysin protein enhanced the in vitro induction of human CTL in the MLC culture (**Table 4A**). In vivo induction of CTL in the spleen was augmented by the administration of recombinant 15K granulyin into C57BL/6 mice (**Table 4B**). The administration of recombinant 15K granulysin also augmented in vivo induction of CTL in the lymph node and PEC (peritoneal exudate cells) (**Table 4B**).

Synergistic effect was observed by the combination of recombinant 15K granulysin and IL-6-related DNA vaccine (IL-6+ IL-6 receptor + gp130 DNA vaccine). In vivo induction of CTL specific for HSP65 TB antigen was augmented by the combination of two vaccines (data not shown). Two types of granulysin vaccines (recombinant 15K granulysin and 15K granulysin DNA vaccine) showed strong therapeutic efficacy in the mice infected with TB by aerosol challenge, resulted in the decrease of the number of C.F.U. in the lungs, liver and spleen (data not shown).

The granulysin (15K) has function as a CTL differentiation factor (**Fig. 5**). It augmented the differentiation of CTL from

precursor CTL into effecter CTL. Thus, this is a first report that reveals the novel function of 15K granulysin (inducer of CTL differentiation). Effector CTLs produce 15K granulysin which induces the differentiation of CTL. Thus, there is a positive feedback loop (or autocrine system) in the regulation of the production of 15K granulysin. Granulysin (15K) might efficiently induce TB-specific CTL and enhance its therapeutic effect against TB infection by means of such a positive feedback loop system (**Fig. 5**).

CTL induction by Ksp37 vaccine. To investigate the immune function of Ksp37 protein, in vitro CTL induction by the addition of recombinant Ksp37 protein was analyzed in murine system. Splenic T cells from C57BL/6 were cultured with alloantigen (BALB/c spleen cells) in the presence or absence of recombinant Ksp37 for five days.

Induction of in vitro CTL differentiation was observed by the addition of recombinant Ksp37 (**Fig. 6**), suggesting that Ksp37 has function as a CTL differentiation factor.

IL-2 production from T cells and spleen cells was augmented by the addition of Ksp37 protein (**Fig. 7A**). Ksp37 also augmented the production of IFN-γ and IL-6 from murine spleen cells in vitro (**Fig. 7B and C**). Thus, Ksp37 is an inducer of multiple types of cytokines (IFN-γ, IL-2 and IL-6).

In order to study the immune function of Ksp37 in vivo, induction of CTL by the administration of Ksp37 DNA vaccine was investigated in murine system. Augmentation of CTL differentiation in vivo in the PEC was observed by the treatment with Ksp37 DNA vaccine (**Fig. 8**). Thus, Ksp37 DNA vaccine functioned as an inducer of CTL in vivo as well as in vitro. Furthermore, synergistic effect on the in vitro CTL induction was observed by the simultaneous treatment of Ksp37 and granulysin vaccines (**Fig. 9**).

Taken together, we established three kinds of novel vaccines and examined their potential in the mouse and monkey models in vitro and in vivo.

We demonstrated that: (1) HSP65+IL-12/HVJ-E DNA vaccine (HSP65 vaccine) had a prophylactic effect against TB. We revealed the induction of CD8+ CTL and CD4+ T cell were required for the protective efficacy of HSP65 vaccine. We also confirmed currently available vaccine (BCG vaccine) induced a little or no TB-specific CTL; (2) We also revealed the 15K granulysin functioned as a cytotoxic T cell differentiation factor (CTL differentiation factor). The production of granulysin is regulated by the positive feedback system. Thus, granulysin-based vaccine might have a strong therapeutic potency against TB, since it is expected to effectively induce TB-specific CTL;

Figure 3. Induction of CD8 positive CTL against TB by HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine, and differentiation of CTL.

(3) We also revealed that Ksp37 acts as a CTL differentiation factor in human and mouse. Ksp37 vaccine augmented the production of IL-2, IFN-γ, and IL-6 from murine T cells and spleen cells; (4) We also demonstrated the synergy of the vaccines, e.g., synergistic effect on the in vitro CTL induction was shown by the combination of Ksp37 and granulysin DNA vaccines.

These data indicate that all of our novel vaccines are able to induce the TB-specific CTL effectively and the combination regimen of those vaccines might provide the new strategy to get very strong protective and therapeutic efficacy against TB.

Discussion

In the present study, we studied the CTL differentiation against TB induced by the administration of novel vaccines (HSP65+IL-12/ HVJ-E DNA vaccine, granulysin vaccine and Ksp37 vaccine). We found (1) 15K granulysin functions as a cytotoxic T cell differentiation factor (CTL differentiation factor). The therapeutic efficacy of 15K granulysin vaccine might be mediated by the induction CTL; (2) Ksp37 also acts as a CTL differentiation factor in mice; (3) Ksp37 vaccine induces the production of IL-2, IFN-γ and IL-6 from murine T cells and spleen cells; (4) Synergistic effect on the in vitro CTL induction is expected by the combination of Ksp37 vaccine and granulysin vaccine.

On the other hand, it was demonstrated that HSP65 +IL-12/ HVJ-E DNA vaccine (HSP65 vaccine) has a prophylactic efficacy against TB and that the induction of CTL specific for TB is important for the efficacy of the vaccine. By using CD8 antibody and CD4 antibody we found CD8 positive CTL and CD4 positive T cell were required for the protective efficacy of HSP65

Table 2. The in vivo necessity CD8 positive T cells and CD4 positive T cells for prophylactic efficacy of the HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine

	Vaccination			Antibody	Log$_{10}$ CFU of TB in the lung
	1st	2nd	3rd		
G1	-	-	-	-	6.6 ± 0.3
G2	BCG	DNA	DNA	-	5.3 ± 0.3
G3	BCG	DNA	DNA	αCD8 Ab	5.9 ± 0.1
G4	BCG	DNA	DNA	αCD4 Ab	7.1 ± 0.5
G5	BCG	DNA	DNA	αCD8 Ab+αCD4 Ab	8.4 ± 0.2

*p < 0.05 G2vsG3, G4; **p < 0.01. G2vsG5, Anti-CD8 antibody and/or Anti-CD4 antibody were injected i.p. every 5 d after the challenge of TB. BCG was used as a prime vaccine and the DNA vaccine was immunized twice (HVJ-Envelope/HSP65 DNA 50 μg + IL-12 DNA50 μg) as boost vaccine. Four weeks after last immunization, 5 × 10^5 H37Rv were challenged i.v. into mice. (G2-G3: p < 0.05); (G2-G4: p < 0.05); (G2-G5: p < 0.01).

vaccine in vitro and in vivo. In contrast, BCG vaccine induced a little or no CTL against TB.

There are increasing evidences which indicate the importance of cytotoxic cells.[3,4] Their role in immunity to TB has been revealed by using knockout mice lacking a gene or genes related to major histocompatibility complex (MHC) class I (e.g., transporter associated with antigen processing-1, CD8, 2m, and MHC class I heavy chain). These genes are involved in the antigen presentation via MHC class I, by cell-transfer experiments and by depletion of CD8+ CTLs with antibodies. CD8+ CTLs play a major role in the control of the latent TB.[1,4,6]

Figure 4. IFN-γ and IL-2 production efficacy of HSP65+IL-12/HVJ and BCG using prime-boost method against TB challenged cynomologus monkeys. Group of animals were vaccinated three times (every three weeks) with (1°) BCG Tokyo, (2°) HSP65 +IL-12/HVJ, (3°) HSP65+IL-12/HVJ = G1(■) BCG prime-HVJ/DNA boost group; (1°) HSP65+IL-12/HVJ, (2°) HSP65 +IL-12/HVJ, (3°) BCG = G2(□) HVJ/DNA prime-BCG boost group; (1°) HSP65+IL-12/HVJ, (2°) HSP65 +IL-12/HVJ, (3°) HSP65+IL-12/HVJ = G3(▩); (1) BCG, (2°) saline, (3°) saline = G4(▥) G4 group animals were vaccinated with BCG once.; (1°) saline, (2°) saline, (3°) saline = G5(▤). (A) PBL from vaccinated monkeys on 56 d or 112 d after 1st immunization, were cultured for three days. IFN-γ activity on 56 d and IL-2 activity (B) on 112 days were assessed by ELISA.

The CTLs other than CD8⁺ cells might be even more important in humans. It has been reported that there are additional effector modalities, such as granulysin, that are able to kill *M. tuberculosis*.[12] Lymphocyte subsets that recognize antigens presented by molecules other than MHC class 1 were also reported to be involved in the immunity against TB. In addition to MHC class 1 molecule, these lymphocytes are able to utilize HLA-E or group1 CD1 molecules (CD1a, CD1b, etc.) for the recognition of antigens.[6,13,14]

The precise function of 15K granulysin has not yet been elucidated.[15] We found that 15K granulysin was secreted from CD8 positive CTL and entered into human macrophages followed by the killing of *M. tuberculosis* in the cytoplasm.[10,11] The expression levels of 15K granulysin protein and mRNA in CD8 positive T cells of the patients with drug sensitive TB were lower than that of the healthy volunteers. Among the TB patients, the expression level of 15K granulysin protein in CD8 positive T cells of the patients with multi-drug resistant tuberculosis (MDR-TB) was significantly lower than that in the patients with drug-sensitive TB. The expressions of 15K granulysin after the stimulation with PHA-P, ConA, alloantigens or PPD antigens were significantly suppressed in the supernatants of PBL from MDR-TB patients.[10,11] We have currently established 15K granulysin transgenic mice and 9K granulysin transgenic mice.[11] It was demonstrated that 15K granulysin transgenic mice as well as 9K granulysin transgenic mice were resistant to TB infection. The number of TB (C.F.U. in tissues) was decreased in those transgenic mice. As to the induction of anti-TB immunity, differentiation and proliferation of TB-specific CTL was augmented in those transgenic mice. In addition, enhanced production of cytokines was observed.

In the present study, we demonstrated that 15K granulysin has function as a CTL differentiation factor. Granulysin (15K) augmented the differentiation of CTL from precursor CTL into effecter CTL. It has been reported that 15K granulysin is produced from effector CTL. Thus, it is suggested that the production of 15K granulysin is regulated by positive feedback loop system. Large amount of granulysin might enhance the induction of CTL resulting in the increase of the therapeutic efficacy. Recently, it was reported that 15K granulysin activated antigen-presenting cells (APC, dendritic cells or macrophages) and augmented the production of several cytokines.[16,17] Therefore, 15K granulysin is able to activate the immune system effectively, since the target cell of it is both APC and CTL.

Vaccination with BCG prime-HSP65 + IL-12/HVJ boost showed better protective efficacy than BCG alone on the basis of the ESR, chest X-ray findings and immune responses. Importantly, treatment with HSP65 + IL-12/HVJ resulted in an increased survival for over a year.[5]

Significantly higher levels of cytokine production from PBL (IFN-γ and IL-2) were observed in prime (BCG) - boost (HSP65 vaccine) group than those in BCG vaccine group. Prime-boost method was reported in the study of MVA85A vaccine, which is a modified vaccine virus Ankara (MVA) strain expressing antigen 85A. In phase I clinical studies, this vaccine has induced high immune responses in previously BCG-vaccinated individuals.[18]

Table 3. IL-2 production from PBL in the cynomolgus monkeys

(A)	(monkeys) Responder cell	H37Ra Ag	IL-2 (u/ml)
	vaccine-treated	(-)	2 ± 3
	control	(-)	0 ± 0
	vaccine-treated	(+)	13 ± 4
	control	(+)	3 ± 5

(B)	G4 (saline control)	IL-2 production (U/ml) (HSP65 stimulation)		Survival
	ID of monkeys	Baseline	Day53 Post-challenge	
	PR 6847 D	0.0	21.1	Survival
	PR 8018 B	0.0	43.2	Survival
	PR 5368 B	0.0	43.2	Survival
	PR PbB2–4F	0.0	0.0	Death (after 41 d)
	PrZ7–51 AC	0.0	0.0	Death (after 55 d)

(A) Augmentation of IL-2 production from PBL by H37Ra stimulation in the monkeys treated with HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine. (B) IL-2 production from PBL in the survived monkeys and the non-survived monkeys. PBL from monkeys on day 53 after TB challenge were stimulated with HSP65 protein for 3 d. ID (PR PbB2–4F) monkey and ID (PrZ7–51 AC) were died after 41 d and 55 d, respectively.

Table 4. In vitro and in vivo CTL induction by 15K granulysin

		15K Granulysin	% Specific Cytotoxicity		
(A)	In vitro (5day MLC)				
		-	8.0	±	1.0
		+	23.0	±	0.5
(B)	In vivo CTL				
	spleen	-	1.0	±	0.2
		+	11.0	±	0.3
	LN	-	7.2	±	2.5
		+	22.5	±	2.8
	PEC	-	0.5	±	2.0
		+	28.5	±	1.0

(A) In vitro induction of human cytotoxic T cell by the stimulation with recombinant 15K granulysin protein. T cells from human PBL were obtained by nylon-wool column method. An amount of 1 × 10⁶ T cells were cultured with CESS$_{MMC}$ cells (Mitomycic C treated CESS tumor cells) in the presence of 15K granulysin for five days. CTL activity of effector cells was assayed using ⁵¹Cr-labbelled CESS cells. Results are expressed as % Specific cytotoxicity ± S.D. (B) In vivo induction of CTL by 15K granulysin. C57BL/6 were injected i.p. with 1 × 10⁷ syngeneic FBL-3 tumor cells and then treated with recombinant 15K granulysin i.p. (5 μg/mouse) six times. Twenty-one days after FBL-3 inoculation, mice were sacrificed, and spleen cells, lymph node (LN) cells and peritoneal exudates cells (PEC) were used as effector cells for CTL. Cytotoxic activity against FBL-3 cells were assessed using ⁵¹Cr release method.

Boosting of BCG vaccination with MVA85A reduced the expression of immunoregulatory cytokine TGF-β.[19] Aeras-402 DNA (DNA that expressed 85A, 85B and TB10.4) vaccine is a recombinant adenovirus vector-based vaccine and expected as

Figure 5. Differentiation of CTL by 15K granulysin and positive feedback loop of 15K granulysin in CTL induction. Precursor CTL are activated by IL-2 in the early stage of CTL induction of five day MLC. On the other hand, IL-6 acts, as a cytotoxic T cell differentiation factor, on the late stage of CTL induction as shown by Okada, et al. (J.I. 1988). 15K granulysin is produced from effector CTL, and induced the differentiation of CTL as a CTL differentiation factor. (Positive feedback loop by 15K granulysin).


Figure 6. Induction of CTL differentiation by killer-specific secretory protein of 37Kd (Ksp37). Splenic T cell from C57BL/6 mice (H-2^b) were obtained as described in (PNAS Okada et al. 1981), and cultured with uv-treated BALB/c (H-2^d) spleen cells (Mitomycin C treated) in the presence of 100ng/ml rKsp37 and/or an anti-Ksp37 antibody for 5 d. CTL activity against P815 tumor cells (H-2^d) was assessed by using ^{51}Cr assay.

encoding the same TB antigens (rAd35) is used as a boost vaccine. The prime-boost method using rBCG and rAd35 vaccines were evaluated in nonhuman primate model.[21] Similar to our BCG prime- HSP65 + IL-12 DNA boost method, the results suggested that activation of CD8$^+$ effector CTL followed by the production of granulysin at the local site were involved in the protective effects of this vaccine (prime-boost). Thus, induction of TB-specific CTL and the augmentation of the cytokine production (IFN-γ, IL-2) might be a critical factor to obtain the prophylactic efficacy.

Furthermore, we established other vaccines (granulysin vaccine and Ksp37 vaccine) which induced the differentiation of CTL against TB. The granulysin secreted from T cells and NK cells has a therapeutic effect against TB.

On the other hand, Ksp37 is expressed selectively in the effector subset of CD8$^+$T cells, CD16$^+$ NK cells and γ/δ T cells.[22] Expression of Ksp37 mRNA was closely correlated with good prognosis of ovarian cancer and gliomas.[23] However, immunological function(s) of Ksp37 is still unclear. Ksp37 showed anti-TB effects by the induction of CTL in the present study. We demonstrated that Ksp37 vaccine also induced murine CTL both in vitro and in vivo. Ksp37 vaccine augmented the production of IL-2, IFN-γ and IL-6 from murine T cells and spleen cells. Synergistic effect on the in vitro CTL induction was observed by the combination of Ksp37 and granulysin vaccines. We also demonstrated the correlation between the activity of CTL induction/cytokine production and the efficacy of these vaccines in the mouse and monkey models.

In conclusion, our data might provide novel strategy to obtain strong protective and therapeutic efficacy. The important factors are the induction of CTL and production of several kinds of cytokines. In addition, the combination of several kinds of vaccines will enhance the efficacy of vaccines, which will be necessary for the vaccine for the severe TBs such as MDR-TB and XDR-TB. Similar to the treatment of cancers or infectious diseases, the regimen of combination therapy will provide useful rationale that is necessary to develop more effective vaccines against TB.

Materials and Methods

Bacteria. *M. tuberculosis* strains H37Rv and *M. bovis* BCG Tokyo, were kindly provided by Dr. I. Sugawara (JATA, Tokyo, Japan). *M. bovis* BCG Tokyo was maintained in synthetic Sauton's medium (Wako Chemicals, Osaka, Japan).[1]

Animals. Inbred and specific pathogen-free female BALB/c mice and DBA/1 mice were purchased from Japan SLC (Shizuoka, Japan). Mice were maintained in isolator cages, manipulated in laminar flow hoods, and used between 8 and 10 weeks of age as described previously.[1]

Plasmid construction. The *HSP65* gene was amplified from *M. tuberculosis* H37Rv genomic DNA, and cloned into pcDNA3.1 (+) (Invitrogen, San Diego, CA) to generate pcDNA-hsp65 (designated as HSP65 DNA) as described previously.[1] The *HSP65* gene was fused with mouse Igκ secretion signal sequence, and pcDNA-Ighsp65 was generated. For construction of the mouse IL-12 (mIL-12) *p40* and *p35* single-chain genes, *mIL12p35* and

a boosting vaccine for BCG-primed individuals.[6] Several other vaccines use a prime-boost strategy to enhance the immune responses.[20] Recently, Rahman et al. established a plasmid-based vaccine (rBCG/rAd35 vaccine) which enhanced the activation of MHC class I-restricted CD8$^+$ cytotoxic T cell. It is a recombinant BCG (rBCG) expressing a pore-forming toxin and TB antigens (Ag85A, 85B and TB10.4). A non-replicating adenovirus35

mIL12p40 genes were cloned from pcDNA-p40p35,[1] fused and cloned into pcDNA3.1 (+) to generate pcDNA-mIL12p40p35-F (designated as mIL-12 DNA).

HVJ-E vaccination. HVJ-E was prepared as described previously.[1] The HVJ-E complex was aliquoted and stored at -70°C until use. DNA vaccines encoding *M. tuberculosis* HSP65 and IL-12 were encapsulated into HVJ-Envelope or HVJ-liposomes.[24] HVJ-liposomes and HVJ-Envelope were prepared as described previously.[25-29] Groups of BALB/c mice were vaccinated 3 times at 3-week intervals with 100 μL of HVJ-E solution containing 50 μg of pcDNA-IgHSP65 and 50 μg of mIL12 DNA.

Challenge infection of vaccinated animals and bacterial load determination. Mice were challenged by the intravenous route with 5×10^5 CFU of *M. tuberculosis* H37Rv 4 weeks after the third vaccination as described previously.[1]

Methods for the evaluation of the prophylactic efficacy of the vaccine on the TB infection of the monkeys. Cynomolgus monkeys were housed in a BSL 3 animal facility of the Leonard Wood Memorial Research Center. The animals were vaccinated three times with the HVJ-envelope with expression plasmid of both HSP65 and human IL-12 (HSP65 + hIL-12/HVJ: 400 μg i.m.), and then challenged with the *M. tuberculosis* Erdman strain (5×10^2) by intratracheal instillation. Survival, immune responses (proliferation of PBL and cytokines production), body weight, ESR, PPD skin test and chest X-p findings were examined as described in our previous studies.[5,6,8,9] All animal experiments were approved by the Leonard Wood Memorial Animal Care and Use Committee and the National Hospital Organization Kinki-chuo Chest Medical Center Animal Care and Use Committee.

Methods for the evaluation of the therapeutic efficacy of the vaccine on the *M. tuberculosis*-infected monkeys. Cynomolgus monkeys were vaccinated nine times with the HVJ-envelope with expression plasmid of both HSP65 and human IL-12 (HSP65 + hIL-12/HVJ: 400 μg i.m.), one week after the challenge with the *M. tuberculosis* Erdman strain (5×10^2) by intratracheal instillation. Immune responses and survival were examined as described in our previous studies.[5,8,9]

Reagents and antibodies. Fetal calf serum (FCS: lot AGC6341) was obtained from Hyclone (Logan, UT). Anti-L3T4, anti-Lyt2.2 monoclonal antibodies and anti-Thy1.2 antibody were provided.[1,2]

Cell lines. A mouse mastocytoma cell line (P815: DBA/2 origin) was kindly provided by Dr. C. S. Henney (Fred Hatchinson Cancer Res. Center, Seattle).[1] The P815 cells were maintained in RPMI 1640 medium (Flow Laboratories, Inc. Mclean, VA) supplemented with 10% FCS, penicillin (100 U/ml), streptomycin (100 μg/ml) and 5×10^{-5} M 2-mercaptoethanol.[1,2]

Tuberculosis–specific cytotoxic test using ⁵¹Cr release. Eight weeks after the final vaccination, CTL activity of spleen cells and mesenteric lymph node cells from vaccinated mice was assessed by using the ⁵¹Cr-release assay. P815 mastocytoma cells, which have the same major histocompatibility complex (MHC) ($H-2^d$) as BALB/c mice, were transfected with pcDNA-hsp65 and used as HSP65 protein-expressing target cells. A total of 2 $\times 10^6$ cells/ml effector splenic cells were treated with anti-CD8 antibody, anti-CD4 antibody or anti-Thy1.2 antibody followed


Figure 7. Augmentation of cytokines (IL-2, IFN-γ and IL-6) production by Ksp37 was also observed. (A) Augmentation of IL-2 production from T cells or spleen cells by Ksp37. An amount of 5×10^6 splenic T cells or spleen cells from C57BL/6 mice were cultured with 5×10^5 BALB/c spleen cells (Mitomycin-C treated) in the presence of rKsp37 for two days. IL-2, IFN-γ and IL-6 activities in the supernatants were assessed by ELISA. (B) Augmentation of IFN-γ production from spleen cells by Ksp37. (C) Augmentation of IL-6 production from spleen cells by Ksp37.

Figure 8. Augmentation of CTL differentiation in vivo by the treatment with Ksp37 DNA was demonstrated. C57BL/six mice were challenged with killed H37Ra antigen (1,000 μg/mouse) in vivo (i.p.) and then treated with Ksp37 DNA (100 μg/mouse, six times) i.m. Twenty-one days after challenge of killed TB antigen, and PEC (peritoneal exudate cells) from these mice were harvested. CTL activity againt TB antigen (HSP65 antigen) was assessed by using ⁵¹Cr EL-4 which had been transfected with HSP65 DNA.

by complement.[1] ⁵¹Cr release was assessed using the ⁵¹Cr-release assay[10,30-34] at the Effector:Target (E:T) ratio of 50:1. Spontaneous lysis (with medium alone) and maximum lysis (⁵¹Cr release after three cycles of freeze-thaw) were set up for background and targets. Percent specific lysis was determined as: [(experimental release − spontaneous release)/(maximum release − spontaneous release)] × 100.[30-34]

Production of cytokines (IL-2 and IFN-γ). Mouse cytokines were measured in quantitative ELISAs for IL-2 and IFN-γ as described previously.[1,2]

ELISPOT assay. The spleens were removed aseptically from vaccinated mice 3 weeks after the third vaccination. Antigen-specific IFN-γ-producing cells were determined by enzyme-linked immunosorbent spot (ELISPOT) as described previously.[1,2]

Statistical analysis. Tukey-Kramer's HSD tests were used to compare $\log_{10}$ value of CFU between groups following challenge and T cell responses between groups in ELISPOT assay. Student's t-tests were performed to compare T cell responses between groups in T cell proliferation assay and granuloma formation between groups following challenge. A P-value of < 0.05 was considered significant.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Figure 9. Synergistic efficacy of Ksp37 and granulysin on the in vitro CTL induction. Splenic T cells were cultured with uv-treated BALB/c spleen cells (Mytomycin C treated) in the presence or absence of 100ng/ml Ksp37 protein and 500ng/ml 15K granulysin protein for 5 d. Five days after culture, CTL activity against P815 tumor cells was assessed by using ⁵¹Cr release assay.

References

1. Yoshida S, Tanaka T, Kita Y, Kuwayama S, Kanamaru N, Muraki Y, et al. DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation. Vaccine 2006; 24:1191-204; PMID:16216394; http://dx.doi.org/10.1016/j.vaccine.2005.08.103.

2. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Novel prophylactic vaccine using a prime-boost method and hemagglutinating virus of Japan-envelope against tuberculosis. Clin Dev Immunol 2011; 2011:549281; PMID:21437226; http://dx.doi.org/10.1155/2011/549281.

3. Boom WH. New TB vaccines: is there a requirement for CD8 T cells? J Clin Invest 2007; 117:2092-4; PMID:17671648; http://dx.doi.org/10.1172/JCI32933.

4. van Pinxteren LA, Cassidy JP, Smedegaard BH, Agger EM, Andersen P. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol 2000; 30:3689-98; PMID:11169412; http://dx.doi.org/10.1002/1521-4141(200012)30:12<3689::AID-IMMU3689>3.0.CO;2-4.

5. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Evaluation of a novel vaccine (HVJ-liposome/HSP65 DNA+IL-12 DNA) against tuberculosis using the cynomolgus monkey model of TB. Vaccine 2007; 25:2990-3; PMID:17280753; http://dx.doi.org/10.1016/j.vaccine.2007.01.014.

6. Okada M, Kita Y. Tuberculosis vaccine development: The development of novel (preclinical) DNA vaccine. Hum Vaccin 2010; 6:297-308; PMID:20372079; http://dx.doi.org/10.4161/hv.6.4.10172.

7. Walsh GP, Tan EV, dela Cruz EC, Abalos RM, Villahermosa LG, Young LJ, et al. The Philippine cynomolgus monkey (Macaca fasicularis) provides a new nonhuman primate model of tuberculosis that resembles human disease. Nat Med 1996; 2:430-6; PMID:8597953; http://dx.doi.org/10.1038/nm0496-430.

8. Kita Y, Tanaka T, Yoshida S, Ohara N, Kaneda Y, Kuwayama S, et al. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. Vaccine 2005; 23:2132-5; PMID:15755583; http://dx.doi.org/10.1016/j.vaccine.2005.01.057.

9. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Novel prophylactic and therapeutic vaccine against tuberculosis. Vaccine 2009; 27:3267-70; PMID:19200841; http://dx.doi.org/10.1016/j.vaccine.2009.01.064.

10. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Novel therapeutic vaccine: granulysin and new DNA vaccine against Tuberculosis. Hum Vaccin 2011; 7(Suppl):60-7; PMID:21546794; http://dx.doi.org/10.4161/hv.7.0.14563.

11. Kita Y, Okada M, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Development of therapeutic and prophylactic vaccine against Tuberculosis using monkey and transgenic mice models. Hum Vaccin 2011; 7(Suppl):108-14; PMID:21263229; http://dx.doi.org/10.4161/hv.7.0.14571.

12. Stegelmann F, Bastian M, Swoboda K, Bhat R, Kiessler V, Krensky AM, et al. Coordinate expression of CC chemokine ligand 5, granulysin, and perforin in CD8+ T cells provides a host defense mechanism against Mycobacterium tuberculosis. J Immunol 2005; 175:7474-83; PMID:16301655.

13. Woodworth JS, Behar SM. Mycobacterium tuberculosis-specific CD8+ T cells and their role in immunity. Crit Rev Immunol 2006; 26:317-52; PMID:17073557; http://dx.doi.org/10.1615/CritRevImmunol.v26.i4.30.

14. Lewinsohn DM, Zhu L, Madison VJ, Dillon DC, Fling SP, Reed SG, et al. Classically restricted human CD8+ T lymphocytes derived from Mycobacterium tuberculosis-infected cells: definition of antigenic specificity. J Immunol 2001; 166:439-46; PMID:11123322.

15. Stenger S, Hanson DA, Teitelbaum R, Dewan P, Niazi KR, Froelich CJ, et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 1998; 282:121-5; PMID:9756476; http://dx.doi.org/10.1126/science.282.5386.121.

16. Castiello L, Sromcek DF, Finn MW, Wang E, Marincola FM, Clayberger C, et al. 15 kDa Granulysin versus GM-CSF for monocytes differentiation: analogies and differences at the transcriptome level. J Transl Med 2011; 9:41; PMID:21501511; http://dx.doi.org/10.1186/1479-5876-9-41.

17. Clayberger C, Finn MW, Wang T, Saini R, Wilson C, Barr VA, et al. 15 kDa granulysin causes differentiation of monocytes to dendritic cells but lacks cytotoxic activity. J Immunol 2012; 188:6119-26; PMID:22586033; http://dx.doi.org/10.4049/jimmunol.1200570.

18. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004; 10:1240-4; PMID:15502839; http://dx.doi.org/10.1038/nm1128.

19. Fletcher HA, Pathan AA, Berthoud TK, Dunachie SJ, Whelan KT, Alder NC, et al. Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1. Vaccine 2008; 26:5269-75; PMID:18682270; http://dx.doi.org/10.1016/j.vaccine.2008.07.040.

20. Kaufmann SH, Hussey G, Lambert PH. New vaccines for tuberculosis. Lancet 2010; 375:2110-9; PMID:20488515; http://dx.doi.org/10.1016/S0140-6736(10)60393-5.

21. Rahman S, Magalhaes I, Rahman J, Ahmed RK, Sizemore DR, Scanga CA, et al. Prime-boost vaccination with rBCG/rAd35 enhances CD8+ cytolytic T-cell responses in lesions from Mycobacterium tuberculosis-infected primates. Mol Med 2012; 18:647-58; PMID:22396020; http://dx.doi.org/10.2119/molmed.2011.00222.

22. Ogawa K, Tanaka K, Ishii A, Nakamura Y, Kondo S, Sugamura K, et al. A novel serum protein that is selectively produced by cytotoxic lymphocytes. J Immunol 2001; 166:6404-12; PMID:11342666.

23. Elgaaen BV, Haug KB, Wang J, Olstad OK, Fortunati D, Onsrud M, et al. POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas. PLoS One 2010; 5:e13837; PMID:21079801; http://dx.doi.org/10.1371/journal.pone.0013837.

24. Saeki Y, Matsumoto N, Nakano Y, Mori M, Awai K, Kaneda Y. Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus): reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Hum Gene Ther 1997; 8:2133-41; PMID:9414261; http://dx.doi.org/10.1089/hum.1997.8.17-2133.

25. Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N, et al. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther 2002; 6:219-26; PMID:12161188; http://dx.doi.org/10.1006/mthe.2002.0647.

26. Kaneda Y. New vector innovation for drug delivery: development of fusigenic non-viral particles. Curr Drug Targets 2003; 4:599-602; PMID:14577648; http://dx.doi.org/10.2174/1389450033490740.

27. Kaneda Y, Yamamoto S, Nakajima T. Development of HVJ envelope vector and its application to gene therapy. Adv Genet 2005; 53:307-32; PMID:16240999; http://dx.doi.org/10.1016/S0065-2660(05)53012-8.

28. Ito M, Yamamoto S, Nimura K, Hiraoka K, Tamai K, Kaneda Y. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J Gene Med 2005; 7:1044-52; PMID:15756713; http://dx.doi.org/10.1002/jgm.753.

29. Mima H, Yamamoto S, Ito M, Tomoshige R, Tabata Y, Tamai K, et al. Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin-conjugated HVJ envelope vector. Mol Cancer Ther 2006; 5:1021-8; PMID:16648574; http://dx.doi.org/10.1158/1535-7163.MCT-05-0352.

30. Okada M, Yoshimura N, Kaieda T, Yamamura Y, Kishimoto T. Establishment and characterization of human T hybrid cells secreting immunoregulatory molecules. Proc Natl Acad Sci U S A 1981; 78:7717-21; PMID:6801660; http://dx.doi.org/10.1073/pnas.78.12.7717.

31. Tanaka F, Abe M, Akiyoshi T, Nomura T, Sugimachi K, Kishimoto T, et al. The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene using adenovirus vector. Cancer Res 1997; 57:1335-43; PMID:9102222.

32. Okada M, Sakaguchi N, Yoshimura N, Hara H, Shimizu K, Yoshida N, et al. B cell growth factor and B cell differentiation factor from human T hybridomas. Two distinct kinds of B cell growth factor and their synergism in B cell proliferation. J Exp Med 1983; 157:583-90; PMID:6600487; http://dx.doi.org/10.1084/jem.157.2.583.

33. Okada M, Klimpel GR, Kuppers RC, Henney CS. The differentiation of cytotoxic T cells in vitro. I. Amplifying factor(s) in the primary response is Lyt 1 + cell dependent. J Immunol 1979; 122:2527-33; PMID:156228.

34. Okada M, Sakaguchi N, Yoshimura N, Hara H, Shimizu K, Yoshida N, et al. B cell growth factors and B cell differentiation factor from human T hybridomas. Two distinct kinds of B cell growth factor and their synergism in B cell proliferation. J Exp Med 1983; 157:583-90; PMID:6600487; http://dx.doi.org/10.1084/jem.157.2.583.

Novel therapeutic vaccines [(HSP65 + IL-12) DNA-, granulysin- and Ksp37-vaccine] against tuberculosis and synergistic effects in the combination with chemotherapy

Yoko Kita,[1] Satomi Hashimoto,[1] Toshihiro Nakajima,[2] Hitoshi Nakatani,[1] Shiho Nishimatsu,[1] Yasuko Nishida,[1] Noriko Kanamaru,[1] Yasuhumi Kaneda,[3] Yasushi Takamori,[4] David McMurray,[5] Esterlina V. Tan,[6] Marjorie L. Cang,[6] Paul Saunderson,[6] E.C. Dela Cruz[6] and Masaji Okada[1,*]

[1]Clinical Research Center; National Hospital Organization Kinki-chuo Chest Medical Center; Kitaku, Sakai Japan; [2]Ikeda Laboratory; GenomIdea Inc.; Midorigaoka, Ikeda; [3]Division of Gene Therapy Science; Graduate School of Medicine; Osaka University; Suita, Osaka Japan; [4]Department of Periodontology; Tsurumi University School of Dental Medicine; Tsurumi, Tsurumiku Japan; [5]Texas A&M University; System Health Center; College of Medicine; College Station, TX USA; [6]Leonard Wood Memorial Institute; Cebu, Philippines

Purpose: Multi-drug resistant tuberculosis (MDR-TB) and extremely drug resistant (XDR) TB are big problems in the world. We have developed novel TB therapeutic vaccines, HVJ-Envelope/HSP65 + IL-12 DNA vaccine (HSP65-vaccine), granulysin vaccine and killer specific secretory protein of 37kDa (Ksp37) vaccine.

Results and Methods: HSP65 vaccine showed strong therapeutic effect against both MDR-TB and XDR-TB in mice. Intradermal immunization of HSP65-vaccine showed stronger therapeutic effect against TB than intramuscular or subcutaneous immunization. Furthermore, the synergistic therapeutic effect was observed when the vaccine was administrated in combination with Isoniazid (INH), which is a first line drug for chemotherapy. The combination of types of vaccines (HSP65- and granulysin- vaccines) also showed synergistic therapeutic effect. In the monkey model, granulysin-vaccine prolonged the survival period after the infection of TB and long-term survival was observed in vaccine-treated group. We examined the potential of two kinds of novel DNA vaccines (Ksp37-vaccine and granulysin-vaccine). Both vaccines augmented in vivo differentiation of CTL against TB. We measured the amount of Ksp37 protein in human serum and revealed that the level of Ksp37 protein of patients with tuberculosis was lower than that of healthy volunteers. Therefore, we established Ksp37 transgenic mice as well as granulysin transgenic mice to elucidate the function of those proteins. Both transgenic mice were resistant to TB infection.

Conclusion: These data indicate the potential of combinational therapy; the combination of two DNA vaccines or combination of DNA vaccine with antibiotic drug. Thus, it will provide a novel strategy for the treatment of MDR-TB.

Introduction

Tuberculosis is a major global threat to human health, with about 2 million people dying every year from Mycobacterium tuberculosis (TB) infection. The only tuberculosis vaccine currently available is an attenuated strain of Mycobacterium bovis BCG (BCG), although its efficacy against adult TB disease remains controversial. Furthermore, multi-drug resistant tuberculosis (MDR-TB) and extremely drug resistant TB (XDR-TB) are becoming big problems in the world. About 500,000 of people around the world are affected by MDR-TB every year. However, there are a small number of effective drugs against MDR-TB. In such circumstances, the development of therapeutic as well as prophylactic vaccines against TB is required.

Cynomolgus monkey model is the best animal TB model to evaluate the potential of newly developed vaccines as reported by Walsh and Tan.[1] Onset and progress after TB infection in the cynomolgus monkey is very similar to human TB disease.[1-3] SCID-PBL/hu is an IL-2 receptor γ-chain disrupted mouse (NOD-SCID) transplanted with human PBL. It is an in vivo humanized immune model and provides an useful tool for investigating human immune responses to the administration

Table 1. Therapeutic efficacy of HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine on TB infection in murine models

1. HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine showed therapeutic efficacy against MDR-TB as well as drug-sensitive TB in mice.

2. Significant prolongation of survival was observed in the XDR-TB infected mice by the treatment with this vaccine.

3. Therapeutic efficacy of this vaccine on chronic TB disease models using a mouse infected with TB in the aerosol chamber was demonstrated.

Therapeutic efficacy of HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine was evaluated by using mouse models. Therapeutic efficacies of this vaccine on the MDR-TB infection and XDR-TB infection were observed.

of vaccines.[4,5] Transgenic mice that express the components of vaccine also provide a lot of information about novel TB vaccines. Therefore, we used three animal models (cynomolgus monkey model of TB, SCID-PBL/hu mice and transgenic mice) to develop three kinds of novel vaccines against TB.

We have previously evaluated a novel therapeutic TB vaccine which consists of plasmid DNA encoding HSP65 + IL-12 and HVJ-Envelope (HSP65-vaccine) and revealed the efficacy of the vaccine in these animal models.[6-9] However, it is very important to treat the patients with TB completely within a short period of time. Therefore, we improved the regimen of the vaccination. We first examined a combination therapy of vaccination and chemotherapy. In the present study, we used a HSP65-vaccine for the vaccination and first line TB drugs (INH or RFP) for the chemotherapy. We next identified a suitable administration route to increase the efficacy of the DNA vaccine. The result suggested that intradermal vaccination is more suitable for the DNA vaccine than intramuscular or subcutaneous vaccination.

Finally, we developed plasmid-based DNA vaccines encoding the granulysin or Ksp37. Granulysin is a member of the saposin-like protein family and colocalizes with perforin and granzymes in the cytolytic granules of human CTL and NK cells. In the presence of perforin, it has a cytolytic activity against intracellular pathogens in the cytoplasm of infected cells. It also has a cytotoxic effect on tumor cells.[10-12] Granulysin is present in cytoplasm of human CD8 positive cytotoxic T cells and NK cells. It has been suggested that granulysin has a cytolytic activity against M. tuberculosis outside macrophages and reduces the number of M. tuberculosis in the macrophage dependent on the presence of perforin in vitro.[11] However, the precise role of granulysin in vivo has not been elucidated yet. Therefore, we have established granulysin transgenic mice to elucidate in vivo role of granulysin and obtain the information to develop novel vaccines against M. tuberculosis. Transgenic mice of 15K and 9K granulysins were resistant to TB infection in vivo. This is the first report indicating an in vivo role of granulysin in the defense against the infection of TB. In addition, we demonstrated the efficacy of granulysin-vaccine in the monkey model of TB.

Ksp37 is also produced from CTL and NK cells.[13] However, immunological function of Ksp37 has not been elucidated yet. In the first step, we first examined the amount of Ksp37 in the serum of patients with TB. The result indicated that Ksp37 in

the serum of patients with TB was lower than that of healthy volunteer. In the next step, we have established Ksp37 transgenic mice to elucidate the in vivo role on Ksp37 in the immunity to the infection of M. tuberculosis. Ksp37 transgenic mouse was resistant to the infection of TB, suggesting the anti-TB effect of Ksp37 in vivo.

To increase the efficacy of the vaccine, we examined the synergistic effect of the combination therapy, in which HSP65-vaccine and first line chemotherapy drug (INH) were administrated. We also examined the synergistic effect of the combination of two kinds of DNA vaccines. HSP65- and granulysin-vaccine were simultaneously administrated in the murine models of TB and efficacy of the vaccines was evaluated in vivo.

In parallel, we investigated the immunological effects of granulysin and Ksp37 and revealed the synergistic effect of two molecules on the induction of TB-specific CTL (manuscript submitted).

These findings demonstrated that granulysin-vaccine and Ksp37-vaccine might provide very useful weapon as TB vaccines, and those efficacy will be enhanced in combination with other DNA vaccine (including HSP65 vaccine) and INH.

Results

Novel therapeutic vaccine of HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine. *Therapeutic effect of the vaccine in murine models of TB.* Therapeutic efficacy of HSP65 DNA + IL-12 DNA vaccine (HSP65-vaccine) was evaluated in murine models. At 30 d after intravenous challenge of MDR-TB, the CFUs of TB in the lungs, spleen, and liver were counted and therapeutic efficacy of HVJ-Envelope DNA vaccine was evaluated.

Table 1 shows the feature of novel TB vaccines; the vaccine consists of a plasmid DNA vaccine expressing mycobacterial heat shock protein 65 (HSP65)+interleukin-12 (IL-12) and a vector (hemagglutinating virus of Japan (HVJ)-liposome or HVJ-envelope). We used the mouse model in our previous study.[6,7] This vaccine showed therapeutic effect against TB in the mouse: (1) This vaccine significantly decrease the number of drug sensitive H37Rv TB in the spleen and the lung of mice (data not shown). This vaccine also decreased the number of MDR-TB in the lungs and spleen of mice, indicating the efficacy of the vaccine in the mouse model of TB. (2) Significant prolongation of survival was observed in the XDR-TB infected mice. The survival period of the mouse treated with this vaccine was prolonged compared with non-vaccinated mice. Those results demonstrated that this vaccine have strong therapeutic effect against XDR-TB. (3) We have established the mouse model of chronic TB disease using an inhalation system (aerosol chamber) for the infection of TB. By using this model, therapeutic efficacy of this vaccine was examined. The vaccine was administered 5 weeks after aerosol infection of TB. Treatment with this vaccine decreased the number of TB in the lung of the mice (data not shown).

Thus, we demonstrated that this vaccine had a therapeutic effect against XDR-TB and MDR-TB as well as drug-sensitive TB.

Synergistic effect of HVJ-Envelop/HSP65 DNA + IL-12 DNA vaccine in combination with INH against TB infection. To enhance the

Figure 1. Synergistic therapeutic efficacy of HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine and INH on TB infection of mice. BALB/c mice were infected with H37Rv TB by using intratracheal aerosol challenge using aerosol chamber. One week after challenge of TB, the vaccine and INH (0.03mg/mouse) were administered 6 times for 3 weeks. Five weeks after TB challenge, mice were sacrified, and CFU of TB in the spleen were evaluated. G1 vs. G2; p < 0.05; G1 vs. G3; p < 0.05; G3 vs. G5; p < 0.05; G2 vs. G5 p < 0.05; Student's test.


Figure 2. Synergistic therapeutic efficacy of HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine and INH on TB infection of mice. BALB/c mice were infected with H37Rv TB by using intratracheal aerosol challenge using aerosol chamber. One week after challenge of TB, the vaccine and INH (0.03mg/mouse) were administered 6 times for 3 weeks. Five weeks after TB challenge, mice were sacrified, and CFU of TB in the liver were evaluated. G2 vs. G4; p < 0.05; G3 vs. G4; p < 0.05; Student's test.

efficacy, we examined synergistic effect of combinational therapy of this vaccine and INH (isoniazid) on the infection of TB. The numbers of TB in the mouse spleen and liver were significantly decreased compared with the monotherapy, indicating the synergistic effect of the combinational therapy (**Figs. 1 and 2**).

We also compared the administration route of the vaccine to improve the regimen of the therapy. We selected three routes (intradermal, intramuscular and subcutaneous injections) for our experiment. The efficacy of intradermal administration (i.d.) was highest among three administration routes (**Fig. 3**).

Therefore, in the monkey model we plan to study the efficacy of intradermal injection of this vaccine, in comparison to i.m administration.

IL-2 receptor γ-chain gene disrupted SCID-PBL/hu. We have very important humanized immune model (SCID-PBL/hu) to study the human T cell immune response in vivo as reported first in Cancer Research 1997.[4] We evaluated the efficacy of novel vaccines in vivo using this humanized immune model.

We used IL-2 receptor γ-chain gene knockout mouse-based model (NOD SCID-PBL/hu) to analyze the human T cell responses to the vaccine (**Table 2**).

The efficacy of HSP65+ IL-12 DNA vaccine was examined in this IL-2 receptor γ-chain gene disrupted SCID-PBL/hu-model and significant decrease of the number of TB in the liver was observed as shown in **Table 2A**. This model shows stronger human CTL induction and proliferation than conventional SCID mouse-based model (CB17-SCID-PBL-hu) (**Table 2B**).

Therapeutic efficacy of this vaccine on monkey model. We are developing a GMP level of DNA vaccine that contains two expression units in one plasmid vector for future clinical trial. In this study, we used a GMP level of DNA vaccine for the evaluation of the potency in the monkey model of TB. Monkeys were intratracheally instillated with 5×10^2 CFU of human TB (Erdman strain). After TB infection, 9 times intramuscular injection of this vaccine (total 400 μg/monkey) was conducted. Therapeutic efficacy was evaluated on the basis of survival, ESR, body weight, immune responses, chest X-ray and PPD skin test. The monkey group treated with HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine showed 100% survival (data not shown). In contrast, the monkey group of control saline showed 60% survival. Thus, the therapeutic DNA vaccine improved the survival rate of TB-infected monkeys, compared with the saline (control).

These data indicated the therapeutic efficacy of a GMP-level of DNA vaccine in TB-infected monkeys.

Efficacy of granulysin-vaccines. *Efficacy of granulysin in transgenic mice.* We noticed the in vivo function of granulysin, since it shows a cytolytic activity against Mycobacterium tuberculosis. The features of granulysin are as follows:

(1) Granulysin is cytolytic molecules expressed by human CTL and NK cells and show the cytolytic activity against a variety of tumors and microbes, including Mycobacterium tuberculosis. Granulysin belongs to the saposin-like protein family that includes amoebapores and NK lysine. Recent studies show that granulysin also has chemoattractant and proinflammatory activities. However, in vivo anti-microbe activity and anti-tuberculosis activity of granulysin has not been elucidated yet.

(2) It has been reported that the granulysin has the function of in vitro cytotoxic activity against M. tuberculosis outside the macrophage cells, and contributes the in vitro reduction of M. tuberculosis in the macrophage in the presence of perforin.

(3) However, the precise role of granulysin in the in vivo against the tuberculosis infection has not been elucidated yet. Therefore, we have established granulysin transgenic mice to elucidate mechanism of granulysin in vivo. We have established two kinds of transgenic mice by using usual microinjection method: 15K granulysin transgenic mice and 9K granulysin transgenic

$\log_{10}$ (CFU)

- G1: i.d
- G2: i.m
- G3: s.c

spl log colony

n=8, 9

* P<0.05
Tukey-Kramer's test

Figure 3. Therapeutic efficacy of intradermal (i.d.) vaccination of HVJ-Envelope/HSP65 DNA + IL-12 DNA, compared with intramuscular (i.m.) or subcutaneous (s.c.) vaccination using intratracheally aerosol infected DBA/1 mice. DBA/1 mice were infected with H37Rv TB by using intratracheal aerosol challenge using aerosol chamber. One week after challenge of TB, 100μg of HVJ-Envelope/HSP65 DNA + IL-12 DNA were administered 6 times for 3 weeks by i.d, i.m, or s.c administration. Four weeks after TB challenge, mice were sacrified, and CFUs of TB in the spleen were evaluated. G1 vs. G2; p < 0.05; G1 vs. G3; p < 0.05; Student's test.

Effect of granulysin on Tuberculosis and TB-infected mouse

|	Anti- TB effect	Induction of Cytotoxic T against TB	Proliferaion of T cells against TB	Cytokine Production (γ-IFN)
15K granulysin Transgenic mouse	++	++	++	++
9K granulysin Transgenic mouse	++	+	+	++

Figure 4. The establishments of 15K granulysin transgenic mice and 9K granulysin transgenic mice. The efficacies of 15K granulysin transgenic mice and 9K granulysin transgenic mice on TB infection were summarized in this Figure. An anti-TB effect, the induction of CTL against TB, the proliferation of T cells against TB and γ-IFN production were augmented in these transgenic mice, compared with wild type C57BL/6 mice.

mice. We measured CFU number of *M. tuberculosis* in the lung four weeks after intravenous injection of TB (5×10^5 /mouse). As shown in **Table 3**, reduction of CFU number was observed in 15K granulysin transgenic mice compared with the normal C57BL/6 mice, indicating the in vivo anti-TB effect of 15K granulysin. As summarized in **Figure 4**, augmentation of immune responses were also observed in 15K granulysin transgenic mice: in vivo induction of cytotoxic T cells against TB, enhanced proliferation of T cells stimulated with TB antigen and augmentation of cytokine production. Furthermore, we examined synergistic effects of the combination of two vaccines. As shown in **Figure 5**, the combination of HSP65-vaccine and granulysin-vaccine showed synergistic effects and 10 times reduction of the CFU number in the liver of TB-infected mice was observed. The number of TB in the liver was significantly reduced by the combination of two vaccines.

Efficacy of granulysin-vaccine in monkey models. We examined the efficacy of granulysin-vaccine in the therapeutic model of TB. The survival rate of granulysin-vaccine (HVJ-Envelope/15K granulysin DNA vaccine)-treated group was 25% (1/4) at 1 y after TB infection (**Fig. 6**). In contrast, all monkeys in saline group were died within 200 d after TB challenge. Thus, survival rate at one year after TB infection was 0% (0/4).

The proliferation of PBL from the monkeys treated with granulysin-vaccine was augmented compared with that of control (saline treated) monkeys (**Fig. 7**). These results indicated the efficacy of granulysin-vaccine in therapeutic models using monkey. Thus, granulysin-vaccine is effective in the monkey as well as the mouse model of TB.

Efficacy of Ksp37-vaccine in therapeutic models. Ksp37 protein is produced from CTL, TypeI helper T cell, γ/δ T cell and NK cell. Ksp37 is composed of 223 amino acids. We analyzed the concentration of Ksp37 in the serum of patients with TB by ELISA. The level of Ksp37 protein in the serum of patients with TB (n = 31) was significantly lower than that of healthy volunteers (n = 60) (p < 0.05) (**Fig. 8**). This is first report suggesting the relation between the serum level of Ksp37 and TB disease (**Fig. 8**).

Therefore, we tried to elucidate the in vivo function of Ksp37 protein, especially function as an anti-TB agent in vivo.

In the first step, we have established a Ksp transgenic mouse for the analysis of function in vivo. We measured the CFU number of M. tuberculosis in the lung 3 weeks after TB aerosol infection. In Ksp transgenic mice, the CFU number of M. tuberculosis was decreased compared with that of wild type control mice (**Fig. 9**). This result indicated the anti-TB effect of Ksp37 in vivo.

These finding suggested that Ksp37 produced from CTL and NK cell functions as an important anti- TB factor in humans and mice.

Discussion

In the present study, we evaluated the potential of three kinds of novel therapeutic vaccines (HSP65-, granulysin- and Ksp37-vaccines) in mouse and monkey models of TB. All of the vaccines showed anti-TB effects in therapeutic models. It is noteworthy

Figure 5. Therapeutic effect of granulysin DNA vaccine on TB-infected (DBA/1) mice DBA/1 mice were infected with H37Rv TB using intratracheal aerosol challenge. One week after challenge of TB, 100μg of HVJ-Envelope/HSP65 DNA + IL-12 DNA and/or 100 μg of HVJ-Envelope/granulysin DNA were injected i.m. into mice 6 times for 3 weeks. Four weeks after TB challenge, mice were sacrified, and CFUs of TB in the liver were evaluated. G1 vs. G2; p < 0.05; G1 vs. G3; p < 0.05; Student's test.


Figure 6. Therapeutic efficacy (survival) of HVJ-Envelope/15K granulysin DNA vaccine, 365 d after TB infection using cynomolgus monkey models. Five × 10² M. tuberculosis (Erdman strain) were intratracheally into cynomolgus monkeys as described in Materials and Methods. Four weeks after challenge of TB, 400μg of HVJ-Envelope/15K granulysin were injected i.m. Six times every two weeks. Survival of monkeys treated with this vaccine were evaluated for 1 y (365 d).

that efficacy of novel therapeutic vaccines were demonstrated in monkey models as well as murine models. Thus, this is the leading report of new vaccine against TB. According to our knowledge, only a few therapeutic vaccines against TB have been reported.[14,15] HSP65-vaccine as well as 15K granulysin-vaccine delivered by HVJ-Envelope vector prolonged the survival and augmented the immune responses in the cynomolgus monkey model which closely mimics human TB disease. Thus, we are taking advantage of the availability of multiple animal models and are accumulating essential data on the DNA vaccine/HVJ-envelope in anticipation of initiating a phase I clinical trial.

It is very important to evaluate the long-term survival in a monkey model, as human TB is a chronic infection disease. Thus, it is necessary for the development of effective vaccine to evaluate the long-term survival of monkey.[2,3,7-9] In this study, increase in the survival rate was also observed in HVJ-Envelope/15K granulysin vaccine-treated group, compared with saline-treated group (control group). In addition, it is noteworthy that histopathological improvement was observed in the lung of vaccine-treated monkey (365 d after TB infection). A lot of granulomatous lesions were observed in lung of survived monkey, while a little or no such lesions were observed in lung of saline-treated monkey, which had died of TB within 200 d after TB challenge. Histology of granulomatous lesions observed in this experiment was very similar to human lung TB granuloma by histopathological examinations.

Efficacy of 15K granulysin-vaccine was studied in murine models of TB. We used therapeutic models in this experiment. Furthermore, we examined the synergistic effect of two vaccines (the combination of HSP65- and granulysin-vaccines) in the same therapeutic model. The results indicated the synergistic effect of the combinational vaccination. Therefore, the combination of these therapeutic vaccines might be useful for the development of vaccines against human TB infectious disease. In summary, it was demonstrated that granulysin-vaccine had a therapeutic effect against TB in the mouse and monkey models of TB.

We also elucidated the in vivo function of Ksp37. Ksp37 is expressed in cytotoxic lymphocytes, selectively in the effector subset of CD8⁺ T cells, CD16⁺ NK cells and γ/δT cells.[13] Expression of Ksp37 mRNA was closely correlated with good prognosis in ovarian cancer cells and gliomas.[16,17] However,

Table 2. Therapeutic efficacy and Immune responses using IL-2 receptor γ-chain gene disrupted SCID-PBL/hu models

(A) Therapeutic efficacy

Treated	CFU of TB (log)
(-)	6.03 ± 0.06
HSP65 DNA + IL-12 DNA vaccine	5.40 ± 0.97

(B)

Immune reponses	human CTL and T cell proliferation
IL-2 R γ-chain(-/-) SCID PBL-hu	human CTL (+++) human T cell proliferation (+++)
CB17-SCID PBL-hu	human CTL (+) human Tcell proliferation (+)

Therapeutic efficacy of HVJ-envelope / HSP65DNA + IL-12DNA, using in vivo humanized immune models of IL-2 receptor γ-chain disrupted NOD-SCID mice (SCID-PBL/hu). Groups of animals were treated with 3 times with HVJ-envelope / HSP65DNA + IL-12DNA (50ug i.m.). Ten days after the third vaccination, mice were sacrificed and CFU of TB in the liver of mice were accessed as described in Materials and Methods. One × 10⁷ PBL from a healthy human volunteer were injected i.p. into IL-2 receptorγ-chain disrupted NOD-SCID mice. Twenty one days after injection of PBL, mice were challenged with 5 × 10⁵ H37Rv i.v. and then treated with vaccine. *Student's t-test was used to compare the CFU of TB of each group (p < 0.05). Human immune responses [human CTL activity and human T cell proliferation against alloantigen (CESS cells)] of IL-2 receptor γ-chain (-/-) NOD SCID PBL-hu mice were compared with those of CB17-NOD-SCID PBL-hu mice. (+), weak; (+++), very strong.

Table 3. In vivo anti-TB effect of 15kDa Granulysin Transgenic mouse

mouse	lung Number of M. tuberculosis 4 weeks after TB injection (log)
G1 15K Granulysin Tg	5.3 ± 0.35
G2 Wild Type C57BL/6	6.0 ± 0.5

Mean ± SD, n = 7; *p < 0.05 G1 vs. G2; Tukey-Kramer's HSD; In vivo inhibition of the growth of *M. Tuberculosis* in the 15K granulysin transgenic mice; In vivo anti-TB effect of 15K granulysin transgenic mouse; Five 15 K granulysin transgenic mice and five wild type C57BL/6 mice were injected with 5 × 10⁵ H37Rv M. tuberculosis i.v. Four weeks after the challenge of *M. Tuberculosis*, mice were sacrificed. CFU of *M. Tuberculosis* in the lungs of these mice were assessed described in Material and Methods. Student's t-test was used (p < 0.05).

detailed immunological function has not been elucidated yet. We first revealed that the level of Ksp37 protein in the serum of patients with TB was lower than that of healthy volunteer. The result suggested the relation between the serum level of Ksp37 and TB disease. Next, we have established Ksp37 transgenic mice to elucidate the in vivo role of Ksp37 in the defense against the infection of M. tuberculosis. Ksp37 transgenic mice showed in vivo anti TB effect. Thus it was demonstrated that Ksp37 played an important role in anti-TB function in human as well as mice bodies. Finally, we examined the efficacy of Ksp37-vaccine in the mouse model of TB. Similar to granulysin-vaccine, Ksp37-vaccine augmented in vivo differentiation of CTL against TB (data not shown). In addition, simultaneous administration of Ksp37- and granulysin-vaccines induced CTL generation synergistically (data not shown). Therefore, these findings indicate that granulysin- and Ksp37-vaccine might provide very useful weapon as a novel TB vaccine, in the monotherapy or combination therapy.

The HSP65 vaccine showed a significant therapeutic effect against TB, as described previously: (1) Prolongation of survival of mice infected with XDR-TB; (2) Decrease in the CFU of TB in lung, liver and spleen of mice infected with MDR-TB as well as drug-sensitive TB (H37Rv); (3) Decrease in the CFU of TB in organs of mice challenged with TB in the in vivo humanized immune model of SCID-PBL/hu.

Here, we revealed the synergistic effects of the combination therapy of HSP65-vaccine and a first line chemotherapy drug Isoniazid (INH). It is very important to make a suitable regimen, which enables the treatment of the patient with TB to complete within a shorter period. In such circumstances, our data demonstrating the synergistic effect of the combinational therapy using a DNA vaccine and a chemotherapy drug will provide a new strategy for the treatment of TB.

We also revealed the importance of administration route of DNA vaccine. Generally, vaccines are administrated either intradermally (i.d.), intramuscullary (i.m.) or subcutaneously (s.c.). Our data suggested that the intradermal injection is suitable for the administration of our DNA vaccines. Therefore, in the monkey model we plan to conduct the efficacy study of intradermal injection of this vaccine. We will compare the efficacy of intradermal administration to conventional i.m administration.

In the recent study using cynomologus monkeys, it is suggested that i.d. vaccination of HSP65-vaccine showed stronger therapeutic effects against TB than i.m. vaccination on the basis of the prolongation of survival and ESR (Erythrocyte Sedimentation Rate).

DNA vaccine is a relatively new approach of immunization for infectious diseases.[3,4,18-21] We have developed a hemagglutinating virus of Japan envelope (HVJ-Envelope) using inactivated Sendai virus, as a nonviral vector for drug delivery.[22-24] It can efficiently deliver DNAs, siRNAs, proteins and anti-cancer drugs into cells both in vitro and in vivo.[25-27] Therefore, HVJ-Envelope was suitable as an efficient and safe vector for DNA vaccines.

The priority of development of vaccine(s) to prevent reactivation of TB will be increased, since large proportion of the world is latently infected with TB. The combination of HSP65-vaccine with conventional vaccine (BCG) showed synergistic effects in the mouse and monkey models of TB and prolonged the survival of animals. Therefore, it will be important to evaluate the current vaccines as post-exposure vaccines. Combination of several vaccines or combination of vaccines with drugs for chemotherapy might provide a new insight for the prevention of the reactivation of TB.

In conclusion, our data indicated the synergistic therapeutic effect of combination of HSP65-, granulysin- and Ksp37-vaccines or combination of these DNA vaccines and first line chemotherapy drug(s). Combinational therapy using vaccines and antibiotics might provide novel rationale against MDR-TB therapy. Furthermore, the efficacies of HSP65 vaccine and granulysin vaccine were confirmed in the murine therapeutic model for XDR-TB and cynomolgus monkey therapeutic model. These data will provide a rationale for moving this vaccine into clinical trial. HSP65-, granulysin- and Ksp37-vaccines might be useful


Figure 7. Proliferation of PBL from monkeys vaccinated with HVJ-Envelope/15K granulysin DNA by the stimulation with HSP65 antigen. Five × 10² M. tuberculosis (Erdman strain) were intratracheally into cynomolgus monkeys as described in Materials and Methods. Four weeks after challenge of TB, 400µg of HVJ-Envelope/15K granulysin were injected i.m. Six times every two weeks. The proliferation of PBL from monkeys vaccinated with HVJ-Envelope/15K granulysin on 13 weeks after TB challenge were assessed by the ³H-TdR uptake of lymphocyte for 3 d culture.

vaccines against TB including XDR-TB and MDR-TB after the clinical trials.

Materials and Methods

Methods for the evaluation of the therapeutic efficacy of the vaccine on the *M. tuberculosis*-infected monkeys. Cynomolgus monkeys were housed in a BL 3 animal facility of the Leonard Wood Memorial Research Center. The animals were vaccinated nine times with the HVJ-envelope with expression plasmid of both HSP65 and human IL-12 (HSP65 + hIL-12/HVJ: 400 ug i.m.), one week after the challenge with the *M. tuberculosis* Erdman strain (5 × 10²) by intratracheal instillation. Immune responses and survival were examined as described in our previous studies.[2,6,7]

The animals were vaccinated with HVJ-Envelope/15K granulysin DNA vaccine 6 times. Four weeks after challenge of TB, 400 μg of HVJ-Envelope/15K granulysin were injected i.m. six times every two weeks. Survival of monkeys treated with this vaccine were evaluated. All animal experiments were approved by the Leonard Wood Memorial Animal Care and Use Committee and the National Hospital Organization Kinki-chuo Chest Medical Center Animal Care and Use Committee.

Methods for the evaluation of the efficacy of vaccines on the *M. tuberculosis*-infected mice. DNA vaccines encoding *M. tuberculosis* HSP65 and IL-12 were encapsulated into HVJ-Envelope.[3,6,8,28] HVJ-Envelope were prepared as described previously1.[4,29] The HVJ-Envelope complex was aliquoted and stored at -70°C until use. Groups of mice were vaccinated three times with 100 μl of HVJ-Envelope solution containing 50 μg of pcDNA-IgHSP65 and 50 μg of pcDNA-mIL12p40p35-F in the tibia both anterior muscles after TB challenge.[28,29] At 30 d after intravenous challenge of *M. tuberculosis* H37Rv and MDR-TB, the number of CFU in the lungs, spleen, and liver were counted and therapeutic efficacy of HVJ-Envelope DNA vaccines was evaluated.[28,29] DBA/1 mice were treated with HVJ-Envelope/HSP65 DNA + IL-12 DNA vaccine three times i.m. at 1, 8 and 15 d after the challenge of 5 × 10⁵ CFU MDR-TB i.v. Therapeutic efficacy was also evaluated by chronic TB infection model of mice using aerosol challenge of TB (15CFU/mouse: Madison aerosol exposure chamber, University of Wisconsin). Mice were maintained in isolator cages, manipulated in laminar flow hoods and used between 8–10 weeks of age. All vaccinations and experiments on isolate tissue of animal were done under anesthetic state with sevoflurane. Infected animals were housed in individual micro-isolator cages in a Biosafety Level (BL) 3 animal facility of the NHO Kinki-chuo Chest Medical Center. All animal experiments were approved by the National Hospital Organization Kinki-chuo Chest Medical Center Animal Care and Use Committee.

Methods for the establishment of SCID-PBL/hu model. IL-2 receptor γ-chain disrupted NOD-SCID-PBL/hu was constructed as described in our previous study.[4,5] CTL activity was assessed using the method as described previously.[30-32]

Methods for the establishment of granulysin transgenic mouse. Either 15K granulysin gene, 9K granulysin gene or secreted 9K granulysin DNA (15K Gra secretory signal DNA was fused into N-terminal of 9K granulysin DNA) were transferred


Figure 8. Killer specific secretory protein of 37kDa (Ksp37 protein) in the serum of patients with tuberculosis. Ksp37 protein in the serum of 31 patients with TB and 60 healthy volunteers were assessed by ELISA.


Figure 9. In vivo anti-TB effect of Ksp37 transgenic mice. Ksp37 Tg mice were established as described in Materials and Methods. Ksp37 Tg mice, 15K granulysin Tg mice, 9K graunlysin Tg mice and wild type C57BL/6 mice were infected with H37Rv TB by using intratracheal aerosol challenge using aerosol chamber.

to expressing plasmid DNA (pCAGGS) having CAG promoter. DNA fragment was injected to pronuclei embryo and grafted to 200 foster parents. Two types of 15K granulysin Tg mice, 3 types of 9K granulysin Tg mice and 6 types of secreted 9K granulysin Tg mice were made. Granulysin activity was assessed by monoclonal antibody targeting 15K granulysin and 9K granulysin. *Mycobacterium tuberculosis* H37Rv 5 × 10⁵ CFU was intravenously injected to 15K granulysin Tg mice, 9K granulysin Tg mice, wild type (control) mice and normal C57BL/6 mice (8–12weeks).[3,7] From 2 to 12 weeks after injection, these mice were sacrificed. The lungs, the liver and the spleen of these mice were removed, homogenized and cultivated for 14 d on 7H11 agar medium. Then, the number of colony of *Mycobacterium tuberculosis* was measured.[28,29]

Method for the establishment of Ksp37 transgenic mouse. Ksp37 gene were transferred to expressing plasmid DNA

153

(pCAGGS) having CAG promoter. DNA fragment was injected to pronuclei embryo and grafted to 200 foster parents. Two types of Ksp Tg mice (#13, #14) were made. Ksp activity was assessed by monoclonal antibody targeting Ksp 37.

Reagents. Isoniazid (INH) was obtained from Sigma Co. Ltd (lot No. 117K0712). Rifampicin (RFP) was obtained from Sigma Co. Ltd (lot No. 087K18753). An amount of 0.03 mg/mouse of INH and 0.1 mg/mouse of RFP were administered to mice per os.

Statistical analysis. Student's t tests and Tukey-Krumer's test were used to compare log 10 value of CFU between groups following challenge of TB. Student's t tests were also performed to compare immune responses between groups in T cell proliferation assay. A P-value of < 0.05 was considered significant.

References

1. Walsh GP, Tan EV, dela Cruz EC, Abalos RM, Villahermosa LG, Young LJ, et al. The Philippine cynomolgus monkey (Macaca fasicularis) provides a new nonhuman primate model of tuberculosis that resembles human disease. Nat Med 1996; 2:430-6; PMID:8597953; http://dx.doi.org/10.1038/nm0496-430.

2. Kita Y, Tanaka T, Yoshida S, Ohara N, Kaneda Y, Kuwayama S, et al. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. Vaccine 2005; 23:2132-5; PMID:15755583; http://dx.doi.org/10.1016/j.vaccine.2005.01.057.

3. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Evaluation of a novel vaccine (HVJ-liposome/HSP65 DNA+IL-12 DNA) against tuberculosis using the cynomolgus monkey model of TB. Vaccine 2007; 25:2990-3; PMID:17280753; http://dx.doi.org/10.1016/j.vaccine.2007.01.014.

4. Tanaka F, Abe M, Akiyoshi T, Nomura T, Sugimachi K, Kishimoto T, et al. The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene using adenovirus vector. Cancer Res 1997; 57:1335-43; PMID:9102222.

5. Okada M, Okuno Y, Hashimoto S, Kita Y, Kanamaru N, Nishida Y, et al. Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models. Vaccine 2007; 25:3038-40; PMID:17289225; http://dx.doi.org/10.1016/j.vaccine.2007.01.032.

6. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Novel prophylactic and therapeutic vaccine against tuberculosis. Vaccine 2009; 27:3267-70; PMID:19200841; http://dx.doi.org/10.1016/j.vaccine.2009.01.064.

7. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Novel therapeutic vaccine: granulysin and new DNA vaccine against Tuberculosis. Hum Vaccin 2011; 7(Suppl):60-7; PMID:21546794; http://dx.doi.org/10.4161/hv.7.0.14563.

8. Kita Y, Okada M, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Development of therapeutic and prophylactic vaccine against Tuberculosis using monkey and transgenic mice models. Hum Vaccin 2011; 7(Suppl):108-14; PMID:21263229; http://dx.doi.org/10.4161/hv.7.0.14571.

9. Okada M, Kita Y. Tuberculosis vaccine development: The development of novel (preclinical) DNA vaccine. Hum Vaccin 2010; 6:297-308; PMID:20372079; http://dx.doi.org/10.4161/hv.6.4.10172.

10. Peña SV, Hanson DA, Carr BA, Goralski TJ, Krensky AM. Processing, subcellular localization, and function of 519 (granulysin), a human late T cell activation molecule with homology to small, lytic, granule proteins. J Immunol 1997; 158:2680-8; PMID:9058801.

11. Stenger S, Hanson DA, Teitelbaum R, Dewan P, Niazi KR, Froelich CJ, et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 1998; 282:121-5; PMID:9756476; http://dx.doi.org/10.1126/science.282.5386.121.

12. Huang LP, Lyu SC, Clayberger C, Krensky AM. Granulysin-mediated tumor rejection in transgenic mice. J Immunol 2007; 178:77-84; PMID:17182542.

13. Ogawa K, Tanaka K, Ishii A, Nakamura Y, Kondo S, Sugamura K, et al. A novel serum protein that is selectively produced by cytotoxic lymphocytes. J Immunol 2001; 166:6404-12; PMID:11342666.

14. Rook GAW, Lowrie DB, Hernàndez-Pando R. Immunotherapeutics for tuberculosis in experimental animals: is there a common pathway activated by effective protocols? J Infect Dis 2007; 196:191-8; PMID:17570105; http://dx.doi.org/10.1086/518937.

15. Kaufmann SH, Hussey G, Lambert PH. New vaccine for tuberculosis. Lancet 2010; 375:2110-9; http://dx.doi.org/10.1016/S0140-6736(10)60393-5.

16. Elgaaen BV, Haug KB, Wang J, Olstad OK, Fortunati D, Onsrud M, et al. POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas. PLoS One 2010; 5:e13837; PMID:21079801; http://dx.doi.org/10.1371/journal.pone.0013837.

17. Yamanaka R, Arao T, Yajima N, Tsuchiya N, Homma J, Tanaka R, et al. Identification of expressed genes characterizing long-term survival in malignant glioma patients. Oncogene 2006; 25:5994-6002; PMID:16652150; http://dx.doi.org/10.1038/sj.onc.1209585.

18. Huygen K. DNA vaccines: application to tuberculosis. Int J Tuberc Lung Dis 1998; 2:971-8; PMID:9869111.

19. Lowrie DB. DNA vaccines against tuberculosis. Curr Opin Mol Ther 1999; 1:30-3; PMID:11249680.

20. Hoft DF. Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet 2008; 372:164-75; PMID:18620952; http://dx.doi.org/10.1016/S0140-6736(08)61036-3.

21. Gupta UD, Katoch VM, McMurray DN. Current status of TB vaccines. Vaccine 2007; 25:3742-51; PMID:17321015; http://dx.doi.org/10.1016/j.vaccine.2007.01.112.

22. Saeki Y, Matsumoto N, Nakano Y, Mori M, Awai K, Kaneda Y. Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus): reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Hum Gene Ther 1997; 8:2133-41; PMID:9414261; http://dx.doi.org/10.1089/hum.1997.8.17-2133.

23. Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N, et al. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther 2002; 6:219-26; PMID:12161188; http://dx.doi.org/10.1006/mthe.2002.0647.

24. Kaneda Y. New vector innovation for drug delivery: development of fusigenic non-viral particles. Curr Drug Targets 2003; 4:599-602; PMID:14577648; http://dx.doi.org/10.2174/1389450033490740.

25. Kaneda Y, Yamamoto S, Nakajima T. Development of HVJ envelope vector and its application to gene therapy. Adv Genet 2005; 53:307-32; PMID:16240999; http://dx.doi.org/10.1016/S0065-2660(05)53012-8.

26. Ito M, Yamamoto S, Nimura K, Hiraoka K, Tamai K, Kaneda Y. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J Gene Med 2005; 7:1044-52; PMID:15756713; http://dx.doi.org/10.1002/jgm.753.

27. Mima H, Yamamoto S, Ito M, Tomoshige R, Tabata Y, Tamai K, et al. Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin-conjugated HVJ envelope vector. Mol Cancer Ther 2006; 5:1021-8; PMID:16648574; http://dx.doi.org/10.1158/1535-7163.MCT-05-0352.

28. Yoshida S, Tanaka T, Kita Y, Kuwayama S, Kanamaru N, Muraki Y, et al. DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against *Mycobacterium tuberculosis* by T cell activation. Vaccine 2006; 24:1191-204; PMID:16216394; http://dx.doi.org/10.1016/j.vaccine.2005.08.103.

29. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Novel prophylactic vaccine using a prime-boost method and hemagglutinating virus of Japan-envelope against tuberculosis. Clin Dev Immunol 2011; 2011:549281; PMID:21437226; http://dx.doi.org/10.1155/2011/549281.

30. Okada M, Yoshimura N, Kaieda T, Yamamura Y, Kishimoto T. Establishment and characterization of human T hybrid cells secreting immunoregulatory molecules. Proc Natl Acad Sci U S A 1981; 78:7717-21; PMID:6801660; http://dx.doi.org/10.1073/pnas.78.12.7717.

31. Okada M, Sakaguchi N, Yoshimura N, Hara H, Shimizu K, Yoshida N, et al. B cell growth factors and B cell differentiation factor from human T hybridomas. Two distinct kinds of B cell growth factor and their synergism in B cell proliferation. J Exp Med 1983; 157:583-90; PMID:6600487; http://dx.doi.org/10.1084/jem.157.2.583.

32. Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol 1988; 141:1543-9; PMID:3261754.

リファンピシン単独耐性結核菌の分子疫学的解析

[1]吉田志緒美　　[1]露口　一成　　[2]鈴木　克洋　　[3]富田　元久

[1]岡田　全司　　[2]林　　清二　　[4]岩本　朋忠

要旨：〔目的〕リファンピシン（RFP）単独耐性結核菌の遺伝子解析。〔方法〕初回・既治療を合わせた新規入院患者由来結核菌4,633株中RFPのみ耐性であった15株を用いてhot spotを含むrpoB遺伝子シークエンス解析を行い，VNTRによる各菌株の遺伝的異同を検討した。〔結果〕15株中14株にコドン531，526，516，533上のrpoB変異が認められた。また，VNTRにより同一パターンを示すグループの存在が明らかとなった。〔考察〕今回全体に占めるRFP単独耐性菌の割合は低いため，これらの株が市中伝播している可能性は低いが，経年的に散発している傾向にあり，RFP単独耐性株の地域拡散が懸念された。

キーワーズ：結核菌，Rifampicin，rpoB遺伝子，薬剤感受性検査，VNTR

はじめに

わが国の2009年における全結核患者数は24,170人であり，罹患率は10万対19.0と前年と比べて約2％の減少にとどまっている[1]。また，治療が困難な多剤耐性結核菌（MDR-TB）感染は結核対策上の重要な問題であるが，2002年の結核療法研究協議会が実施した全国調査によると，多剤耐性率は初回・再治療を合わせて1.9％（60/3,122）となっている[2]。2009年結核サーベイランスによる新登録肺結核菌培養陽性患者による登録時薬剤感受性結果から初回・再治療を合わせた多剤耐性率は0.8％（56/6,920）であり，多剤耐性率の減少がみられるが20〜40歳代の年代層に耐性結核患者が目立つ[1]。これに対して世界では，2008年には44万人がMDR-TB感染であるとされ，2009年の結核新規登録患者940万人の3.3％がMDR-TBであると推定されている（WHO推計）[3]。世界の結核罹患状況から鑑みて，わが国は中蔓延国ではあるが先進国の中では依然高く，地域的に耐性結核菌の増加が懸念されている高蔓延地域に囲まれている環境上，耐性結核菌の早期発見と適切な治療は重要な意味をもつ。

MDR-TBが生まれる背景として，不充分な服薬や中断による獲得耐性が挙げられ，それらの患者は2〜3％の割合で再発すると言われている[4]。一方，不幸にも耐性結核の患者から感染を受けて発病した人は最初から薬剤耐性となってしまう。このような薬剤耐性結核の拡大防止のために，公衆衛生の強化と並んで耐性結核菌の病原性や発症原因に関する研究が従来から行われているが，結核治療において重要な治療薬の一つであるイソニアジド（INH）の単剤耐性結核菌は世界的に高い頻度で分離されているのに比べ，同じく一次抗結核薬であるリファンピシン（RFP）単独耐性の分離頻度は稀であるため，原因究明のための充分な解析がなされていない。本研究では，当センターで分離できたRFP単独耐性結核菌の耐性遺伝子変異と分子疫学的解析を行い，その実態に迫った。

方　　法

〔対　象〕

2001〜2009年の間，当センターに新規入院患者由来でBACTEC MGIT960システム（日本ベクトン・ディッキンソン）と小川KY培地（セロテック）を用いた培養検査で陽性となり，小川培地上でコロニー性状を確認，さらに自家製PNB培地で複数菌の混在を否定した後，アンプリコア・マイコバクテリウムツベルクローシス（ロ

シュ・ダイアグノスティックス）とキャピリアTB（タ
ウンズ）を用いて結核菌群と同定された4,633株を対象
とした。これらの株は一度も治療歴のない初回治療患者
由来の3,644株と過去に治療歴のある既治療患者由来の
989株に分類された。これらの株を再培養し，単一コロ
ニーを採取した後，BACTEC MGIT960 AST（日本ベク
トン・ディッキンソン）とウエルパック−S（日本ビーシ
ージー）を用いて薬剤感受性検査結果を確認した。MGIT-
AST法と小川比率法の結果がともにRFP耐性，INH感受
性とされた15株を遺伝子解析の対象とし，MGIT-AST
でINH（0.1 μg/ml）耐性，小川比率法でINH低濃度（0.2
μg/ml）感受性となった3株は対象から外した。

〔RFP耐性 rpoB 遺伝子のシークエンス解析〕

　Kimらの方法[5]に準じてRFP単独耐性結核菌のシーク
エンス解析を行った。プライマーセットはMF（5'-CGA
CCACTTCGGCAACCG）とMR（5'-TCGATCGGGCACA
TCCGG）を用い，hot spotの81-bpを含む306-bpの rpoB 遺
伝子領域を3500 Genetic Analyzer（Applied Biosystems）
を用いて解析した。得られたデータはBlast解析により，
データベースと比較検討した。

〔VNTR解析〕

　Supplyら[6]によって提唱された国際標準法である15
MIRU-VNTRと，国内標準法として提唱されている
JATA12-VNTR[7]に加えて，わが国で高い分解能をもつ超
多変領域（Hypervariable, HV）の3領域[8]を用いて遺伝
子型別比較を行った。15MIRU-VNTRとJATA12-VNTR
はアガロースゲル電気泳動とキャピラリー電気泳動
（Agilent Technologies），HV領域は3500 Genetic Analyzer
を用いてPCR産物の分子量を算出し，コピー数の換算を
行った。

結　　果

〔RFP単独耐性結核菌の分離頻度〕

　初回治療患者由来3,644株に占めるRFP単独耐性結核
菌の分離頻度は0.4%（13株），INH単独耐性は3.6%（132
株），MDR-TBは1.1%（40株）であった。一方，既治療
患者由来989株における分離頻度は順にRFP単独耐性
0.2%（2株），INH単独耐性は4.6%（45株），MDR-TBは
9.1%（90株）であった。

〔rpoB シークエンス解析結果〕

　RFP単独耐性結核菌15株中14株は rpoB 遺伝子領域に
変異を認めた。これらの株はコドン531に変異を保有す
る9株と526に変異のある3株，516と533に変異が認め
られた各1株ずつであった。rpoB 遺伝子解析で野生型
であった1株はMIC測定で32 μg/ml 以上と判定されたた
め，今回解析対象とした rpoB 遺伝子領域以外に変異を
もっていると考えられた（Table）。

〔VNTR解析〕

　15株のうちすべての領域でVNTRのコピー数が一致
した2株で構成されるグループAと，3株で構成される
グループBが認められ，残り10株はそれぞれに異なる
VNTRパターンを示した。また，今回クラスターを形成
しなかった菌株No.207のVNTRパターンは当センター
における既治療MDR-TB患者2名の由来株と同一であ
った（Table）。

考　　察

　多剤耐性結核や慢性持続排菌者となる原因の一つに既
に耐性菌感染であることを知らずに治療して，残りの感
受性である薬剤を次々に耐性化させてしまうといった人
為的な要素が考えられる。現在の結核治療では単剤治療
は禁忌であり薬剤感受性検査で耐性薬剤を確認すること
は必須であるが，迅速に耐性菌を検出するにはRFP耐性
株の約95%が変異を有する rpoB 遺伝子のコドン507か
らコドン533までの27個のアミノ酸（hot spot領域：81
bp）の遺伝子変異を解析して耐性を確認する方法が有益
である[9]。今回の研究結果から，RFP単独耐性結核菌の
93.3%に rpoB 遺伝子変異が認められ，いずれも hot spot
内の変異であることが認められた。rpoB 遺伝子変異の
割合は高い順にコドン531（60%），526（20%），533と
516（各6.7%）となり，当センターのMDR-TBの割合〔コ
ドン531（62.9%），526（20%），533（5.7%），516（2.9%）：
データ未掲載〕とわが国のMDR-TBの割合[10]とほぼ同じ
となった。しかし，RFP単独耐性結核菌が少ないため
MDR-TBとの間に何らかの有意な違いが示しにくく，さ
らに患者背景等を考慮せねばならないことから直ちに結
論付けることは難しい。

　わが国の2002年の全国調査で，未治療患者の8.6%，
既治療患者の25.2%は主要な抗結核薬のいずれか一つに
耐性をもっており，未治療患者の0.2%，既治療患者の
0.5%はRFPにのみ耐性をもっているという[2]。これらの
RFP単独耐性率は，INH単独耐性率（未治療群1.2%，既
治療群6.2%），MDR-TB率（未治療群0.7%，既治療群
9.8%）に比べて低いが，未治療群よりも既治療群のほう
が高い。本研究で得られた未治療患者におけるRFP単独
耐性，INH単独耐性，MDR-TBの耐性率（順に0.4%，3.6
%，1.1%）と既治療患者群の耐性率（順に0.2%，4.6%，
9.1%）を比べるとほぼ既治療患者群のほうが高く矛盾し
ない。唯一，既治療群のRFP単独耐性率が未治療群より
低いのは菌株数の少なさに影響されたと思われる。しか
し，国際的には既治療患者のRFP単独耐性率は高い傾向
がうかがえ[10~13]，多剤耐性化を未然に防ぐためにRFP単
独耐性結核患者が発見された場合は他の耐性結核と同じ
く慎重に，適切な治療を施す必要がある。

Table Profiles of variable number of tandem repeat (VNTR) recognized as 15 rifampicin mono-resistant *M. tuberculosis* isolates and H37Rv and distribution of the *rpoB* mutations

Isolates no.	Date (YY/MM/DD)	JATA12 (No./Alias (15MIRU-VNTR))												Hypervariable (HV)			Locus for international comparison*						Identical group	Mutation codon no. (the change in nucleotide sequence)
		J01	J02	J03	J04	J05	J06	J07	J08	J09	J10	J11	J12	Q3232	Q3820	Q4120	M04	M16	M40	EC	t30	t39		
		t4	M10	t21	t24	Q11b	VNTR 2372	M26	Q15	M31	Q3336	Q26	Q4156											
153	2005/02/03	4	3	3	3	6	3	7	4	7	5	8	3	15	19	6	2	4	3	4	4	3		526 (cac→gac)
394	2005/04/15	3	3	4	3	5	3	7	2	5	15	9	2	15	9	8	2	3	2	4	4	3		531 (tcg→ttg)
519	2005/06/07	4	1	3	2	9	4	9	4	5	7	8	5	16	14	12	2	3	3	4	4	3		516 (gac→gtc)
852	2005/09/20	4	8	3	2	7	4	7	4	4	10	8	2	10	12	3	2	2	3	4	2	1	A	531 (tcg→ttg)
210	2006/02/27	4	1	3	2	6	4	7	4	3	8	8	5	30	16	9	2	3	3	4	4	4		526 (cac→ctc)
883	2006/10/13	4	8	3	2	7	4	7	4	4	10	8	2	10	12	3	2	2	3	4	2	1	A	531 (tcg→ttg)
929	2006/10/30	4	3	4	3	6	3	4	4	5	7	8	3	13	20	10	2	3	3	4	4	3	B	531 (tcg→ttg)
1045	2006/12/07	2	3	1	3	4	2	5	1	3	12	6	5	5	5	2	2	3	1	4	2	4		none
441**	2007/06/14	4	3	3	2	7	3	7	4	5	7	9	5	15	12	9	2	3	3	4	4	3		531 (tcg→ttg)
207	2008/03/05	4	3	4	3	4	3	7	4	5	7	8	3	14	14	8	2	3	3	4	4	3	***	531 (tcg→ttg)
413	2008/05/29	4	3	4	3	6	3	4	4	5	7	8	3	13	20	10	2	3	3	4	4	3	B	531 (tcg→ttg)
21**	2008/12/17	5	3	2	2	7	3	7	4	5	7	9	5	15	12	8	2	3	3	4	4	4		526 (cac→tac)
103	2009/02/02	3	3	4	3	5	3	7	2	4	17	9	5	12	9	8	2	3	2	4	4	3		533 (ctg→ccg)
923	2009/11/27	4	3	4	3	6	3	4	4	5	7	8	3	13	20	10	2	3	3	4	4	3	B	531 (tcg→ttg)
739	2009/12/07	4	2	4	3	6	1	7	4	5	7	8	4	15	18	10	2	3	3	4	4	3		531 (tcg→ttg)
H37Rv		2	3	1	4	5	2	3	4	3	8	5	3	4	3	2	3	2	1	4	2	5		

*The six loci composed the international Supply's 15MIRU-VNTR by combination with JATA12-VNTR.
**The patients were classified as previously treated.
***The VNTR pattern were concordant with pattern of MDR-TB strains from 2 patients.